BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 30
• 31

• Business

  AVITA Medical to Announce Third Quarter 2022 Financial Results

  AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) announced today that it will report its third quarter 2022 financial results after the close of the U.S. financial markets on Thursday, November 10, 2022.

  October 20, 2022

   · 

  3 min read
• Drug Development

  Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

  Immunic, Inc. (Nasdaq: IMUX) today announced the outcome of a pre-planned interim group-level data analysis of its phase 1b clinical trial of IMU-935 in patients with moderate-to-severe psoriasis.

  October 20, 2022

   · 

  9 min read
• Nyxoah to Participate in the Jefferies London Healthcare Conference 2022

  NyxoahSA announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 15-17, 2022, at The Waldorf Hilton in London.

  October 20, 2022

   · 

  2 min read
• Pharm Country

  Hepion Pharmaceuticals Announces Publication of Food Effect Study with Rencofilstat

  Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) today announced that the peer-reviewed journal, Clinical Pharmacology in Drug Development, has published the results of a clinical trial examining the effect of food on the oral bioavailability of rencofilstat, the Company’s lead drug candidate.

  October 20, 2022

   · 

  4 min read
• Biotech Bay

  Summit Therapeutics Presents Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022

  Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product candidate, ridinilazole, today had an oral podium presentation at IDWeek 2022.

  October 20, 2022

   · 

  13 min read
• Genetown

  Jounce Therapeutics to Present Multiple Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting and the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) Annual Congress

  Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced poster presentations to be made at upcoming medical meetings.

  October 20, 2022

   · 

  6 min read
• Pharm Country

  Biohaven Announces Pricing of Public Offering of Common Shares - October 21, 2022

  Biohaven Ltd. announced the pricing of the public offering of 25,000,000 of its common shares, at a public offering price of $10.50 per common share.

  October 20, 2022

   · 

  4 min read